EUCTR2013-003668-30-NL进行中（未招募）1 期
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients with Recurrent Gliomas - KING
Karyopharm Therapeutic, Inc.0 个研究点目标入组 110 人开始时间: 2015年10月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Pathologically confirmed diagnosis of GBM (including all histologic variants) with radiographic evidence of recurrent disease after treatment with radiotherapy and temozolomide;
- •2. Age = 18 years;
- •3. Karnofsky Performance Status (KPS) = 60;
- •4. Patients enrolling in the medical arm (Arms B, C, or D) must be on a stable or decreasing dose of corticosteroids (or none) for at least 5 days prior to the baseline CT/MRI;
- •5. Patients must have received prior treatment with radiation therapy and temozolomide (all arms);
- •6. Measurable disease (according to RANO guidelines, within 14 days of starting treatment). Measurable disease after surgery on arm A is not required.
- •7. Written informed consent obtained prior to any screening procedures. Patients must be willing and able to comply with the protocol and aware of the investigational nature of this study.
- •8. Patients must have adequate bone marrow function and organ function within 2 weeks of study treatment as defined by the following laboratory criteria;
- •o Hematopoietic function: total white blood cell count (WBC) = 3000/mm³, absolute neutrophil count (ANC) = 1500/mm³, platelet count = 125,000/mm³; hemoglobin = 9g/dL
- •o Hepatic function: bilirubin < 1.5 times the upper limit of normal (ULN), ALT < 2.0 times ULN, AST < 2.0 times ULN; unless bilirubin elevation is related to Gilbert’s Syndrome for which bilirubin must be <4 times ULN.
- •o Renal function: estimated creatinine clearance of = 30 mL/min, calculated using the formula of Cockroft and Gault or other standard methods at the treating institution..
- •9. All female patients of childbearing potential must agree to use reliable methods of birth control during study treatment and for 3 months after the last dose of study drug and have a negative serum pregnancy test at Screening. Reliable methods of contraception include intrauterine devices, hormonal contraceptives [contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release], abstinence or sterilization of the partner;
- •10. Fertile males must be willing to employ reliable methods of contraception during study treatment and for 3 months after the last dose of study drug.
- •11. Archived paraffin-embedded tissue: approximately 10 unstained slides (if less, contact Sponsor) or a tumor block must be available for correlative studies.
- •12. Patients in the Surgical Arm (Arm A) must be predicted pre-operatively to have sufficiently sized tumor to be resected and provide tissue samples for exploratory assessments.
- •13. Patients enrolling in the medical arm (Arms B, C, or D) must have an interval of at least 12 weeks from completion of radiation therapy and study unless there is histologic proof of active tumor from intervening resection.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Patients must not have significant medical illness that in the Investigator’s opinion cannot be adequately controlled with appropriate therapy or would compromise the patient’s ability to tolerate this therapy.
- •2. <24 days from prior temozolomide, <6 weeks from nitrosourea, <4 weeks from other chemotherapy or investigational agents prior to start of treatment within study.
- •3. Unstable cardiovascular function.
- •4. Known active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg (HBV surface antigen); hepatitis testing is not required.
- •5. Known HIV infection; HIV testing is not required.
- •6. Markedly decreased visual acuity if attributed to other causes than GBM.
- •7. Active infection requiring parenteral systemic antibiotics.
- •8. Patients with coagulation problems and medically significant bleeding in the month prior to start of treatment (e.g., peptic ulcer, epistaxis, spontaneous bleeding). Prior history of DVT or PE is not exclusionary.
- •9. Patients who are pregnant or breast-feeding.
- •10. Other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years.
- •11. Patients must not have significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea or inability to swallow oral medications.
- •12. Dehydration of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade = 1.
- •13. Patients must not have serious psychiatric or medical conditions that could interfere with treatment.
- •14. History of organ allograft.
- •15. Concurrent therapy with approved or investigational anticancer therapeutics.
- •16. Prior treatment with bevacizumab or other direct VEGF/ VEGFR inhibitors. For any question of the definition of a direct VEGF/VEGFR consult Sponsor.
- •17. Arms C and D only: Body Surface area < 1.2 m2, to avoid a dose exceeding the maximum allowable dose of 70 mg/m2.
- •18. Major surgery < 4 weeks prior to the start of study treatment.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients with Recurrent GliomasRecurrent glioblastoma or other brain cancer after failure of radiation therapy and temozolomideMedDRA version: 20.0Level: PTClassification code 10002224Term: Anaplastic astrocytomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073128Term: Anaplastic oligodendrogliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027769Term: Mixed oligo-astrocytomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10026659Term: Malignant oligodendrogliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003668-30-DKKaryopharm Therapeutic, Inc.76
进行中（未招募）
1 期
Phase 2 Study of Idelalisib in Indolent B-Cell Non-Hodgkin LymphomaIndolent B-Cell Non-Hodgkin LymphomaMedDRA version: 20.0Level: PTClassification code 10029601Term: Non-Hodgkin's lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022155-33-DEGilead Sciences, Inc.120
进行中（未招募）
不适用
Efficacy and Safety of SM101 in the Treatment of IgA NephropathyIgA NephropathyMedDRA version: 18.0Level: PTClassification code 10021263Term: IgA nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-002345-64-CZBaxalta Innovations GmbH51
进行中（未招募）
1 期
Phase 2 Study of Idelalisib in Indolent B-Cell Non-Hodgkin LymphomaIndolent B-Cell Non-Hodgkin LymphomaMedDRA version: 20.0 Level: PT Classification code 10029601 Term: Non-Hodgkin's lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022155-33-GBGilead Sciences, Inc.125
招募中
不适用
A Phase 2 Study to Assess the Efficacy and Safety of CMX-020 in Treating Osteoarthritis.osteoarthritisACTRN12616001435471Cytometix A90